Cel-Sci Corporation Common Stock (NY:CVM)

3.904 -0.036 (-0.90%)

Streaming Delayed Price Updated: 11:11 AM EDT, Apr 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Cel-Sci Corporation Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >

CEL-SCI’s Phase 3 Population Analysis for Upcoming Confirmatory Registration Study in Head & Neck Cancer Demonstrates Well Balanced Patient Population, Confidence in Clinical Results

July 26, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Appoints Robert Watson as Chairperson of the Board

July 08, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Presents Head & Neck Cancer Data at Iddst Annual Congress in Budapest: Risk of Death Cut in Half for Patients Treated With Multikine in the Target Population

June 18, 2024

From CEL-SCI Corporation

Via Business Wire

CVM Stock Earnings: CEL-SCI Reported Results for Q2 2024 ↗

May 16, 2024

CEL-SCI just reported results for the second quarter of 2024.

Via InvestorPlace

Why CEL-SCI Corporation (CVM) Shares Are Diving ↗

February 09, 2024

CEL-SCI Corporation shares are trading lower by 13.9% Friday morning. The company priced an offering of 3.875 million shares.

Via Benzinga

Dr. Giovanni Selvaggi, Who Has Brought Several Oncology Drugs to Market, Joins CEL-SCI as Clinical Advisor

June 06, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports Second Quarter Fiscal 2024 Financial Results

May 16, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

May 09, 2024

Via Benzinga

Why CEL-SCI (CVM) Shares Are Trading Higher ↗

May 08, 2024

CEL-SCI shares are trading higher by 18.6% during Wednesday's session. The company received positive feedback from the FDA regarding their cancer immunotherapy.

Via Benzinga

CVM Stock Earnings: CEL-SCI Reported Results for Q4 2023 ↗

December 27, 2023

CEL-SCI just reported results for the fourth quarter of 2023.

Via InvestorPlace

CEL-SCI Receives FDA Go-Ahead for Its Confirmatory Study of Multikine in the Treatment of Head & Neck Cancer

May 08, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Wednesday's Pre-Market Session ↗

May 08, 2024

Via Benzinga

CEL-SCI Appoints Mario Gobbo to Its Board of Directors

April 23, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI’s LEAPS Vaccine Offers Promising New Paradigm to Treat Rheumatoid Arthritis: Published in Frontiers in Immunology

March 19, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Issues Letter to Shareholders

March 06, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Corporation Reports First Quarter Fiscal 2024 Financial Results

February 15, 2024

From CEL-SCI Corporation

Via Business Wire

InvestorNewsBreaks – CEL-SCI Corporation (NYSE American: CVM) Closes on $7.75M Public Offering

February 14, 2024

Via Investor Brand Network

CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock

February 13, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 09, 2024

Via Benzinga

CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock

February 09, 2024

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Completes Commissioning of Its Multikine Manufacturing Facility for Commercial Scale Production of Head & Neck Cancer Drug

February 06, 2024

From CEL-SCI Corporation

Via Business Wire

European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®

January 31, 2024

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

December 28, 2023

Via Benzinga

CEL-SCI Reports Fiscal 2023 Financial Results and Clinical & Corporate Developments

December 22, 2023

From CEL-SCI Corporation

Via Business Wire

12 Health Care Stocks Moving In Monday's Intraday Session ↗

December 04, 2023

Via Benzinga

Why Is Cancer Focused CEL-SCI Stock Trading Higher Today? ↗

December 04, 2023

CEL-SCI Corporation (AMEX: CVM) announced that the British National Institute for Health and Care Excellence (NICE) has selected Multikine (Leukocyte Interleukin, Injection) to be evaluated as the...

Via Benzinga

Why U Power Shares Are Trading Lower By Around 54%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

December 04, 2023

Shares of U Power Limited (NASDAQ: UCAR) shares moved lower during Monday’s session after the company announced pricing of registered follow-on offering of 10 million units at a purchase price of $1.20...

Via Benzinga

UK’S National Institute for Health and Care Excellence (NICE) Selects CEL-SCI’s Multikine as Potential New Standard of Care for Head & Neck Cancer

December 04, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Closing of $5 Million Public Offering of Common Stock

November 20, 2023

From CEL-SCI Corporation

Via Business Wire

CEL-SCI Announces Pricing of $5 Million Offering of Common Stock

November 16, 2023

From CEL-SCI Corporation

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.